Pharmaceutical Cannabis - Poland

Poland

Revenue in the Pharmaceutical Cannabis is projected to reach US$22.25m in 2024.
Revenue is expected to show an annual growth rate (CAGR 2024-2029) of 6.07%, resulting in a market volume of US$29.88m by 2029.
In global comparison, most revenue will be generated in the United States (US$913.10m in 2024).
In relation to total population figures, per person revenues of US$10.89k are generated in 2024.

Market

Region

Region comparison

Currency

Analyst Opinion

The Pharmaceutical Cannabis market in Poland has been experiencing significant growth and development in recent years.

Customer preferences: Customers in Poland are increasingly seeking alternative and natural remedies for various health conditions, leading to a growing demand for pharmaceutical cannabis products. The shift towards more holistic approaches to healthcare is driving consumers to explore the potential benefits of cannabis-based treatments.

Trends in the market: One notable trend in the Pharmaceutical Cannabis market in Poland is the increasing acceptance and legalization of medical cannabis. As regulations evolve and become more favorable towards cannabis-based products, more companies are entering the market to meet the rising demand. This trend is expected to continue as awareness of the potential therapeutic properties of cannabis spreads among both consumers and healthcare professionals.

Local special circumstances: Poland has a unique regulatory environment that is shaping the development of the Pharmaceutical Cannabis market. The country has been gradually expanding access to medical cannabis, creating opportunities for both domestic and international companies to participate in the market. Additionally, the cultural acceptance of alternative medicine practices in Poland is contributing to the growing popularity of pharmaceutical cannabis products.

Underlying macroeconomic factors: The growing Pharmaceutical Cannabis market in Poland is also influenced by broader macroeconomic factors. As the healthcare sector continues to evolve and prioritize patient-centered care, there is a growing acceptance of cannabis-based treatments as a viable option for certain medical conditions. Additionally, the increasing prevalence of chronic diseases and the aging population in Poland are driving the demand for alternative therapies, including pharmaceutical cannabis products.

Methodology

Data coverage:

Data encompasses B2B and B2C enterprises. Figures are based on companies' revenues, funding values and global consumer survey data. Revenues include retail, sales and taxes.

Modeling approach / Market size:

Market sizes are determined by a Top-Down approach, based on a specific rationale for each market market. As a basis for evaluating markets, we use financial reports, third-party data. Next, we use relevant key market indicators and data from country-specific associations such as tobacco spending per capita, medical product spending per capita, consumer spending and consumer spending for recreation purposes, population. This data helps us to estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, S-Curve function, ARIMA time series model and exponential curve function.

Additional Notes:

The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. GCS data is reweighted for representativeness.